510(k) device
Dexcom G7 Continuous Glucose Monitoring System
Dexcom, Inc. · Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ, Class II) · First FDA decision Dec 7, 2022, newest Jun 8, 2026Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
510(k) pathway
Device trials
45
Naming "Dexcom G7"
MAUDE reports
703,434
Brand "Dexcom G7", since 2015
PubMed studies
55
Mentioning "Dexcom G7"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Dexcom G7 Continuous Glucose Monitoring System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System510(k)
K261402 · Decided Jun 8, 2026 · 40 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K253737 · Decided Feb 3, 2026 · 71 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K253710 · Decided Dec 17, 2025 · 23 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: K213919
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38662CGS Administrators, LLCUpdated Sep 29, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38623Wellpoint FederalUpdated Jul 14, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38686WPS Insurance CorporationUpdated Jun 18, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38657Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Home Health Plans of Care: Monitoring Glucose Control in the Medicare Home Health Population with Type II Diabetes MellitusLocal determinationIn effectL35132Palmetto GBAUpdated Apr 9, 2025
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38743Palmetto GBAUpdated Jul 19, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38664First Coast Service Options, Inc.Updated Jun 21, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38617Novitas Solutions, Inc.Updated Jun 21, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Dexcom G7", any status and sponsor, newest update first.
- Interventional Clinical Trial Evaluating COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors in Patients With DiabetesPivotal-lookingRecruiting
CAPTEUR PROTECTNot on our public-company list
NCT07018180 · 194 participants (planned) · Start Dec 5, 2025
Device: Use of COVER patchs for continuous glucose monitoring sensor · For: Diabetes
Sites: Bron, France; Corbeil-Essonnes, France; Grenoble, France · 10 sites in all
- Using Remote Monitoring to Address Health Disparities in Type 2 DiabetesPivotal-lookingEnrolling by invitation
Lawndale Christian Health CenterAcademic, hospital or other
NCT06517576 · 150 participants (planned) · Start Dec 1, 2024 · Primary completion Dec 31, 2026
Device: Blood glucose monitor with Digital Platform and Health Coaching; Continuous glucose monitor · For: Diabetes Mellitus, Type 2
Sites: Chicago, Illinois
- Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage ExerciseRecruiting
Stanford UniversityAcademic, hospital or other
NCT07226583 · 20 participants (planned) · Start Nov 6, 2026 · Primary completion May 2027
Device: netIOB & Exercise Toolkit (NEXT); Continuous Glucose Monitoring and 1 more · For: Type 1 Diabetes Mellitus; Exercise Physiology
Sites: Palo Alto, California
42 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Dexcom G7", and for the whole product code for context.
This brand
703,434 reports: 689,118 malfunction, 13,873 injury, 58 death
Whole product code QBJ
2,390,871 reports: 2,344,654 malfunction, 45,370 injury, 256 death
Newest reports for this brand
3004753838-2026-289462 · Received Oct 30, 2026 · Event dated Oct 14, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Wireless Communication Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2026-289464 · Received Oct 30, 2026 · Event dated Oct 7, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Wireless Communication Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2026-289468 · Received Oct 30, 2026 · Event dated Oct 14, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Wireless Communication Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2574-2026 · Started May 27, 2026 · Posted by FDA Jun 24, 2026
Reason given: Certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process. The sensors were later sold to pharmacies and distributors by Pharmsource, LLC. Lot 1725204004 were designated for destruction because the G7 sensors were not properly sterilized...
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-2163-2026 · Started Apr 14, 2026 · Posted by FDA May 11, 2026
Reason given: A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-2164-2026 · Started Apr 14, 2026 · Posted by FDA May 11, 2026
Reason given: A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Dexcom G7"[tiab]. The summary above synthesizes these.
- A Comparative Analysis of Glycemic Metrics Derived From Three Continuous Glucose Monitoring Systems.
Freckmann G, Wehrstedt S, Eichenlaub M, et al. · Diabetes Care · 2025Comparative Study
- Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes.
Garg SK, Kipnes M, Castorino K, et al. · Diabetes Technol Ther · 2022Research Support, Non-U.S. Gov't
- Performance of the Dexcom G7 Continuous Glucose Monitoring System in Pregnant Women with Diabetes.
Polsky S, Valent AM, Isganaitis E, et al. · Diabetes Technol Ther · 2024Research Support, Non-U.S. Gov't
- Dexcom G7 Accuracy and Reproducibility in the Intensive Care Unit.
Baran JD, Spanbauer C, Bais R, et al. · Diabetes Technol Ther · 2025Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems.
Hanson K, Kipnes M, Tran H · J Diabetes Sci Technol · 2024Comparative Study, Multicenter Study
- Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases.
Almurashi AM, Rodriguez E, Garg SK · J Indian Inst Sci · 2023Review
- Accuracy of the Dexcom G7 Continuous Glucose Monitoring Sensors in People with Diabetes Undergoing Hemodialysis (ALPHA-2 Study).
Avari P, Pushparatnam R, Leelarathna L, et al. · Diabetes Technol Ther · 2025Research Support, Non-U.S. Gov't
- Performance of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes.
Eichenlaub M, Waldenmaier D, Wehrstedt S, et al. · J Diabetes Sci Technol · 2026Comparative Study
- Switching from Intermittently Scanned Continuous Glucose Monitoring to Real-Time Continuous Glucose Monitoring with a Predictive Urgent Low Soon Alert Reduces Exposure to Hypoglycemia.
Preechasuk L, Avari P, Oliver N, et al. · Diabetes Technol Ther · 2024Research Support, Non-U.S. Gov't
- Performance of the DEXCOM G7 CGM system during and after major surgery.
Krutkyte G, Rolfes ED, Herzig D, et al. · Diabetes Obes Metab · 2025Letter
- Designing the Continuous Glucose Monitor Experience: An App Design Process Overview.
Kanter D, Henzler P, Jackson A, et al. · J Diabetes Sci Technol · 2024Research Support, Non-U.S. Gov't
- Using Dexcom G7 in Critically Ill Infant With Hyperinsulinemia on High Frequency Oscillatory Ventilation Support.
Ward CE, Clark T, Velazquez E · HCA Healthc J Med · 2025Case Reports
Other devices of this type
Also filed under product code QBJ.
- Dexcom G6 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · De Novo 2023
- FreeStyle Libre 3 Continuous Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 510(k) 2024
- Dexcom G7 15 Day Continuous Glucose Monitoring SystemDexcom, Inc. · 510(k) 2025
- FreeStyle Libre 2 Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.